This TSX Stock Has Plunged 32% in 2022: Should You Buy the Dip?

Opsens Inc. (TSX:OPS) is a TSX stock that has been pummeled so far in 2022. However, I’m looking to buy the dip right now.

| More on:

Opsens (TSX:OPS) is a Quebec-based company that develops, manufactures, installs, and sells fibre optic sensors for interventional cardiology, fractional low reserve (FFR), oil and gas, and industrial applications. This company’s stock has been hit by turbulence to star this year, despite its exposure to some thriving industries. How should investors view this TSX stock as we move into February? Let’s jump in.

Why Opsens stock has struggled to start 2022

Shares of Opsens have dropped 32% in 2022 as of mid-morning trading on January 31. The stock has declined 7.9% in the week-over-week period. However, its shares are still only down 4.8% year over year.

This TSX stock has succumbed to broader volatility in the Canadian market. However, the fractional flow reserve market is geared up for strong growth going forward. This should spur investors to dive into this dip, as we say goodbye to the first month of 2022.

Fractional flow reserve is a technique that allows one to determine the ratio between the maximum achievable blood flow in a diseased coronary artery and the theoretical maximum flow in a normal coronary artery. MarketsAndMarkets recently projected that fractional flow reserve market is projected to reach US$1.08 billion by 2024. This would represent a CAGR of 16% over the forecast period dating from 2019.

How has this company performed over the past year?

Investors can expect to see Opsens’s next batch of earnings on April 12, 2022. It released its first-quarter fiscal 2022 results on January 13.

The company reported consolidated sales of $8.1 million in Q1 FY2022 — down 3% from the previous year. Meanwhile, coronary artery disease sales declined 7% to $4.9 million. It suffered from a negative exchange rate as well as the continued impact of the COVID-19 pandemic. On the business front, Opsens announced that it filed a 501(k) submission with the United States Food & Drug Administration (FDA). This is for the regulatory clearance of its new guidewire, SavvyWire, for transcatheter aortic valve replacement, or TAVR, procedures. Moreover, it also applied for approval with Health Canada.

Opsens saw administrative and R&D costs rise, as operating expenses hit $6.0 million — up from $4.4 million in the first quarter of fiscal 2021.

Should you buy Opsens today?

Back in the summer of 2020, I’d discussed why investors should get in on healthcare stocks for the long haul. At Opsens, sales of optical medical systems rose to $2.4 million compared to $2.0 million in the prior year. Its exposure to this promising space, as well as other industries, should keep investors interested as we move into the month of February.

Shares of Opsens are trading in favourable value territory compared to its industry peers at the time of this writing. This TSX Stock currently possesses an RSI of 25. That puts Opsens in technically oversold territory, as we finish off the month of January. Investors should look to buy the dip in this promising TSX stock in early 2022.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Investing

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Friday, December 13

Down 1.1% week to date, the TSX Composite Index seems on track to end its five-week winning streak.

Read more »

ETF stands for Exchange Traded Fund
Bank Stocks

A Canadian Bank ETF I’d Buy With $1,000 and Hold Forever

This unique Hamilton ETF gives you 1.25x leveraged exposure to Canada's Big Six bank stocks.

Read more »

a person looks out a window into a cityscape
Dividend Stocks

1 Marvellous Canadian Dividend Stock Down 11% to Buy and Hold Immediately

Buying up this dividend stock while it's down isn't just a smart move, it could make you even more passive…

Read more »

Blocks conceptualizing the Registered Retirement Savings Plan
Dividend Stocks

CPP at 70: Is it Enough if Invested in an RRSP?

Even if you wait to take out CPP at 70, it's simply not going to cut it during retirement. Which…

Read more »

A shopper makes purchases from an online store.
Tech Stocks

The Smartest Growth Stock to Buy With $1,000 Right Now

Given its solid sales growth, improved profitability, and healthy growth prospects, Shopify would be an excellent buy.

Read more »

worry concern
Stocks for Beginners

3 Top Red Flags the CRA Watches for Every Single TFSA Holder

The TFSA is perhaps the best tool for creating extra income. However, don't fall for these CRA traps when investing!

Read more »

Representation of deep learning neural networks and connectivity
Tech Stocks

Opinion: This AI Stock Has a Chance to Turn $1,000 Into $10,000 in 5 Years

If you’re looking for an undervalued Canadian AI stock with huge upside potential, BlackBerry (TSX:BB) should certainly be on your…

Read more »

happy woman throws cash
Dividend Stocks

Step Aside, Side Jobs! Earn Cash Every Month by Investing in These Stocks

Here are two of the best Canadian monthly dividend stocks you can consider buying in December 2024 and holding for…

Read more »